Monday, August 31, 2015

Intraosseous anaesthesia in children with 4 % articaine and epinephrine 1:400,000 using computer-assisted systems

Date: 08 Aug 2015

 

Abstract

Aim

To assess retrospectively the efficacy of computer-assisted intraosseous anaesthesia (CAIO) in children using an anaesthetic solution with a lower concentration of epinephrine (1:400,000).

Methods

In a retrospective study, CAIO was evaluated in healthy children and adolescents for restorative and endodontic treatments, uncomplicated tooth extractions or scalings using articaine 4 % plus epinephrine 1:400,000. Anaesthesia was performed in children who showed enough compliance (score of 0–3 according to modified behaviour Venham scale). Efficacy, amount of anaesthetic solution as well as need of a complementary injection was assessed.

Results

A total of 421 consecutive sessions were performed on 278 patients aged 7.1 ± 2.9 years with 518 teeth involved in the anaesthetic process and analysed process. When teeth to be anaesthetised were considered, the overall success rate was 97.2 %. In most of the cases, only 0.9 mL was needed to achieve anaesthesia. Permanent teeth needed significantly more anaesthetics than primary teeth. Sensitivity of the teeth anaesthetized reappeared in 5.7 % of cases after 30–60 min of treatment.

Conclusions

These results suggest that CAIO with 4 % articaine and epinephrine diluted 1:400,000 can be an alternative to usual infiltration techniques or IO with epinephrine at a higher concentration for most of treatments in primary and permanent teeth. Further studies are needed to evaluate its efficacy in permanent teeth in case of endodontic treatment or extraction.

Friday, August 28, 2015

Citrullination in the periodontium—a possible link between periodontitis and rheumatoid arthritis

Date: 13 Aug 2015

 

Abstract

Objectives

The aim of the present study was to assess human and bacterial peptidylarginine deiminase (PAD) activity in the gingival crevicular fluid (GCF) in the context of serum levels of antibodies against citrullinated epitopes in rheumatoid arthritis and periodontitis.

Materials and methods

Human PAD and Porphyromonas gingivalis-derived enzyme (PPAD) activities were measured in the GCF of 52 rheumatoid arthritis (RA) patients (48 with periodontitis and 4 without) and 44 non-RA controls (28 with periodontitis and 16 without). Serum antibodies against citrullinated epitopes were measured by ELISA. Bacteria being associated with periodontitis were determined by nucleic-acid-based methods.

Results

Citrullination was present in 26 (50 %) RA patients and 23 (48 %) controls. PAD and PPAD activities were detected in 36 (69 %) and 30 (58 %) RA patients, respectively, and in 30 (68 %) and 21 (50 %) controls, respectively. PPAD activity was higher in RA and non-RA patients with periodontitis than in those without (p = 0.038; p = 0.004), and was detected in 35 of 59 P. gingivalis-positive samples, and in 16 of 37 P. gingivalis-negative samples in association with high antibody levels against that species.

Conclusions

PAD and PPAD activities within the periodontium are elevated in RA and non-RA patients with periodontitis. PPAD secreted by P. gingivalis residing in epithelial cells may exert its citrullinating activity in distant regions of the periodontium or even distant tissues.

Clinical relevance

In periodontitis, the citrullination of proteins/peptides by human and bacterial peptidylarginine deiminases may generate antibodies after breaching immunotolerance in susceptible individuals.

Thursday, August 27, 2015

Evaluation of using botulinum toxin (A) in the treatment of myofacial pain syndrome

Available online 8 August 2015

 

Abstract

Myofacial pain syndrome (MPS) is a disorder which has become a topic over the past two decades and nowadays .10 patients (9 female & 1 male) complaining of unilateral MPS were injected with botulinum toxin type A(BTX-A) in masseter and temporalis muscles extra orally under electromyographic guidance (EMG) since they are the primary muscles responsible for pain in ear region and temporal headache respectively, which cause limitation of mandibular movement and development of MPS. EMG evaluation of the results together with clinical one were taken at baseline before injection, after 1, 2, 3 and 6 months following the last injection. The study revealed that BTX-A reduced the severity of symptoms and improve functional abilities for patients with MPS and these extend beyond its muscle - relaxing effects.

Wednesday, August 26, 2015

Minimally-invasive non-surgical approach for the treatment of periodontal intrabony defects: a retrospective analysis.

J Clin Periodontol. 2015 Aug 10. doi: 10.1111/jcpe.12443. [Epub ahead of print]

Abstract

AIM:

The aim of this retrospective analysis was to assess healing of intrabony defects treated with minimally-invasive non-surgical therapy (MINST).

METHODS:

A retrospective analysis was carried out in 35 consecutive intrabony defects treated by MINST (without any adjuncts) in 23 non-smoking patients. All defects had a radiographic intrabony component > 3 mm and had clinical and radiographic data available at baseline and 12 after treatment. Pre- and post-treatment radiographs were analyzed and bone levels were compared by multilevel linear regression adjusted by latent variable method.

RESULTS:

Following MINST, the average PPD and CAL reduction in the intrabony defects were 3.12 mm and 2.78 mm respectively (p<0 .001="" 2.93="" 28.5="" 3.81="" 44.35="" 6.74="" and="" angle="" angles="" associated="" at="" average="" baseline="" by="" change.="" changed="" deeper="" defect="" depth="" depths="" from="" greater="" initial="" intrabony="" less="" mm="" p="" radiographic="" re-evaluation="" reduced="" reduction.="" smaller="" the="" to="" vertical="" was="" were="" while="" with="">

CONCLUSIONS:

This paper shows considerable clinical and radiographic improvements after MINST, therefore bringing evidence to support its efficacy for the treatment of intrabony defects in non- smokers.

Tuesday, August 25, 2015

A new flash-free orthodontic adhesive system: A first clinical and stereomicroscopic study.

Angle Orthod. 2015 Aug 10. [Epub ahead of print]

Abstract

OBJECTIVE:

To analyze the clinical and laboratory properties of the recently introduced APC flash-free orthodontic adhesive.

MATERIAL AND METHODS:

After bonding of 80 brackets on human teeth (group A: APC flash-free adhesive n  =  40, group B: APC Plus adhesive n  =  40), the following measurements were recorded: time for bonding, stereomicroscopic evaluation of excess adhesive, color penetration (methylene blue, 0.5%/24 h), and Adhesive Remnant Index (ARI) score after debonding.

RESULTS:

The time needed for bonding differed significantly between the two groups (A: 19.5 s/tooth vs B: 33.8 s/tooth). The adhesive excess, which was metrically measured from the bracket edge, ranged from 166.27 µm to 81.66 µm (group A) and 988.53 µm to 690.81 µm (group B). After methylene coloration in group A, 52 of 80 measurements showed discoloration on the bracket-adhesive and/or adhesive-enamel interface, while for group B, 78 of 80 were coloration positive. The ARI scores did not differ, with an average ARI score of 2.0 for group A and 2.8 for group B.

CONCLUSION:

The flash-free adhesive significantly reduced the time needed for the bonding process. The excess resin expanded 0.16 to 0.08 mm over the bracket margin. The new technology seems to facilitate a smooth and sufficient marginal surface of the adhesive, which clinically might improve reduction of plaque accumulation.

Monday, August 24, 2015

Dental floss as a possible risk for the development of peri-implant disease: an observational study of 10 cases

 

 

 

 

Abstract

Aim

To report on a possible relationship between the use of dental floss or superfloss and the development of peri-implantitis.

Materials and methods

Ten patients with progressive peri-implantitis with an intensive oral hygiene protocol, which consisted of extensive professional supra- and submucosal cleaning, and not responding to this therapy were scheduled for examination. Plaque and bleeding indices and probing depth measurements were assessed, and radiographic examination was performed every two years.

Results

In all ten cases, remnants of dental floss were found around the neck and coronal part of a dental implant. After careful removal of these floss remnants and implant cleansing, a significant improvement in the peri-implant conditions in nine of ten cases was noted. In one case, peri-implant probing depth decreased substantially. However, bleeding on probing was still present. In vitro testing yielded that the application of various types of dental floss on the exposed rough implant surfaces may easily lead to tearing of floss fibers. This may result in the deposition of floss remnants on rough implant surfaces, which, in turn, may lead to the development of plaque-related peri-implant inflammation and, subsequently, bone loss.

Conclusion

In case of exposed rough surfaces of the dental implant, the peri-implant conditions may be jeopardized by the application of dental floss, and hence, the utilization of interproximal brushes or toothpicks may be preferred for daily home care practices.

Friday, August 21, 2015

Fluoride release and recharging ability of new dental sealants

Abstract

European Archives of Paediatric Dentistry

Aim

This in vitro investigation was to evaluate the fluoride release and recharge abilities of three recently introduced dental fissure sealants (FS).

Methods

Three dental FS were assessed: Teethmate F-1 (Kuraray), Fissurit F (Voco), BeautiSealant (Shofu), and a conventional glass ionomer cement FX-II (Shofu) as a control. Eight cylindrical specimens (7 × 2 mm) of each material were made and immersed individually in 5 ml de-ionized water in plastic containers. Fluoride release of the tested materials was evaluated during the experimental period (28 days) utilising a fluoride ion-selective electrode. At the end of the test period, the specimens were soaked for 5 min in a fluoride solution (0.05 % NaF) and fluoride release was evaluated for the next 5 days. The data were statistically analysed using one-way ANOVA and Bonferroni post hoc test and the level of significance was preset at α = 0.05.

Results

The total fluoride release over the 28-day period for each material was: FX-II (408.6 ± 45.66 μg/cm2) > Teethmate F-1 (89.45 ± 12.32 μg/cm2) > Fissurit F (68.62 ± 8.72 μg/cm2) > BeautiSealant (33.32 ± 4.91 μg/cm2), (p < 0.05). After the re-fluoridation of the specimens with 0.05 % NaF solution the cumulative fluoride re-release during the 5-day period for each material was: FX-II (99.53 ± 13.21 μg/cm2) > Teethmate F-1 (9.76 ± 1.62 μg/cm2) > BeautiSealant (5.69 ± 0.89 μg/cm2) > Fissurit F (4.76 ± 0.72 μg/cm2), (p < 0.05).

Conclusions

The three tested sealants exhibited different capabilities to release and uptake fluoride ions after re-fluoridation but significantly lower than the glass ionomer tested.

Thursday, August 20, 2015

Clinical efficacy of a bleaching enzyme-based toothpaste. A double-blind controlled clinical trial

 

Abstract

Objectives

To assess the efficacy of a bleaching enzyme-based toothpaste.

Material and methods

A randomized clinical trial was carried out, comprising 48 participants with teeth exhibiting color A3 or higher according to the Vita Classical guide. One-half of the sample received the bleaching enzyme-based toothpaste (White Kin®), while the other received placebo toothpaste. Both products were supplied in identical containers and had the same composition except for the active components. The teeth color was measured with a spectrophotometer. The patients were instructed to brush their teeth three times a day during three minutes with the assigned product, during 12 weeks. The color measurements were repeated after 3, 6, 9 and 12 weeks of treatment. Color variation was based on the CIE L*a*b* coordinates, ΔE and the EW index. The relationship of these variables at different observation times were performed using a generalized estimating equations model, which evaluated the effect of treatment, time and interaction.

Results

The patients using the bleaching enzyme-based toothpaste showed an increase in lightness (80.14 -treatment- vs. 79.25 -control group-) and a reduction in component b*. ΔE was found higher in the treatment group (p = 0.064), close to statistical significance.

Conclusions

The bleaching enzyme-based toothpaste could be potentially efficient in the modification in tooth color progressing from the third to ninth week of treatment, tending to stabilize after the ninth week

Clinical relevance

A very low carbamide peroxide concentration, with the incorporation of lactoperoxidase, tooth paste, tends to offer clinically satisfactory results, in terms of modifications in tooth color, nevertheless no significant differences were founded when compared to the control group, with an oral hygiene controlled along the study.

Wednesday, August 19, 2015

Effect of an Experimental Paste with Hydroxyapatite Nanoparticles and Fluoride on Dental Demineralisation and Remineralisation in situ

Table of Contents
Vol. 49, No. 5, 2015
Issue release date: Published online first (Issue-in-Progress)
Section title: Original Paper
Caries Res 2015;49:499-507
(DOI:10.1159/000438466)

Abstract

This study evaluated the effect of an experimental paste containing hydroxyapatite in nanoparticles (nano-HA)/fluoride on dental de-remineralisation in situ. Thirteen subjects took part in this crossover/randomised/double-blind study performed in 4 phases (14 days each). Four sound and 4 pre-demineralised specimens were worn intraorally at each phase corresponding to the following treatments: Nanop Plus (10% HA, 0.2% NaF, nano-HA/fluoride), MI Paste Plus (casein phosphopeptide-amorphous calcium phosphate, 0.2% NaF), F (0.2% NaF) and placebo. Two-hundred and forty enamel and 240 dentine specimens were selected by using surface microhardness; half of them were subjected to pre-demineralisation and the other half remained sound. Sound specimens were further exposed to severe cariogenic challenge (20% sucrose in biofilm) in situ, while pre-demineralised specimens were not. All specimens were exposed to fluoride dentifrice slurry 2 × 1 min/day. Thereafter, the treatments were done for 4 min. The de-remineralisation was quantified by transversal microradiography. The data were statistically analysed by repeated-measures ANOVA/Tukey's tests (p < 0.05). Generally, no huge differences were found among the treatments. However, Nanop Plus was the only treatment able to significantly reduce dentine demineralisation (ΔZ, integrated mineral loss) and to improve enamel remineralisation (ΔΔZ, integrated mineral uptake) compared to placebo. No treatments were able to reduce enamel demineralisation, while for dentine remineralisation all treatments were similarly effective in improving ΔΔZ compared to placebo. Nanop Plus seems to have a positive influence on dental de-remineralisation, which should be further confirmed.

Tuesday, August 18, 2015

NFL Great Emmitt Smith Joins Exciting Lineup of Keynote Speakers At Sirona’s CEREC® 30th (C30) Anniversary Celebration




Former Dallas Cowboys Star Turned Powerful Speaker and Successful Business Entrepreneur to Present at this Year’s Most Anticipated Event in Digital Dentistry

Charlotte, NC (August 12, 2015) – Sirona Dental, Inc., the worldwide leader and pioneers of digital dentistry, recently signed Emmitt Smith, former NFL great and current President and CEO of Emmitt Smith Enterprises, Inc., to appear on stage during its upcoming CEREC® 30th (CEREC 30) Anniversary Celebration. Smith replaces Earvin “Magic” Johnson, Jr., who had to withdraw from C30 due to personal reasons.

Emmitt Smith rose to prominence in the 1990s as the superstar running back of the Dallas Cowboys, and was an integral part of the team’s phenomenal success in winning three Super Bowl championships in a four-year span. Smith culminated his illustrious Hall of Fame career with the proud distinction as having the most rushing yards in NFL history, a record he still holds.

Since his retirement from football in 2005, Smith has successfully transitioned his talents from the gridiron to the business world, founding Emmitt Smith Enterprises (ESE)–an umbrella company of several organizations focusing on areas ranging from real estate to construction. The philanthropic division of ESE, Pat and Emmitt Smith Charities, partners with nonprofits to provide educational and enrichment opportunities to underserved youth.

In addition to becoming a successful business entrepreneur, Smith is a highly sought-after keynote inspirational speaker, and one of the most recognizable brands in sports entertainment. CEREC 30 attendees will be invigorated as they listen to Smith deliver a speech focusing on the determination and perseverance required to achieve success and overcome obstacles.

Michael Augins, president of Sirona Dental, Inc., commented on Smith’s appearance, “Emmitt Smith has established himself as one of the most preeminent examples of a former great athlete turned equally great motivational speaker and entrepreneur. His story and accomplishments embody what a person who overcomes adversity is capable of, and his philanthropic endeavors have had a tremendous impact in providing opportunities to the underprivileged. It’s a joy and honor to have him on hand to speak at our C30 event.”

Sirona’s CEREC 30 event is scheduled at The Venetian® Hotel and The Palazzo® Hotel in Las Vegas September 17-19, 2015. The highly anticipated CAD/CAM educational extravaganza features the leading clinicians in dentistry, in addition to a comprehensive business and leadership curriculum and world-class entertainment. World-renowned life success and leadership coach Tony Robbins headlines an outstanding lineup of electrifying business speakers including Fred Joyal, a leading expert in dental consumer marketing, and Bernie Stoltz, CEO of Fortune Management. The Grammy award-winning rock and roll band Train is set to perform Friday night and CEREC 30 attendees close out the event as they Party Like a Rockstar Saturday night at TAO the Nightclub.

The CEREC 30th Anniversary Celebration will provide up to 18 CE credits across a comprehensive spectrum of digital dentistry topics and tracks, and feature an exhibit hall showcasing top dental companies and their products and services. 

All dental and dental lab professionals are encouraged to visit www.Cerec30th.com for additional information as it becomes available.

About Sirona Dental, Inc.
Sirona, the dental technology leader, has served dealers and dentists worldwide for more than 130 years. Sirona develops, manufactures, and markets a complete line of dental products, including CAD/CAM restoration systems (CEREC), digital intra-oral, panoramic and 3D imaging systems, dental treatment centers, and handpieces. Visit www.sironausa.com for more information about Sirona and its products.
# # #

Monday, August 17, 2015

Ceramir Crown & Bridge recieves the “Best of Class” Technology Award for the third consectutive year.


PRIDE INSTITUTE “BEST OF CLASS” TECHNOLOGY FAIR

Chicago, IL - July 24, 2015 - Now in its seventh year, the Pride Institute’s “Best of Class” Technology Award continues unparalleled in its integrity and approach to recognizing excellence in dental innovation. In 2015, Cermamir Crown & Bridge from Doxa Dental, Inc. is one of those lauded as “Best of Class.”
“To be honored as ‘Best of Class’ is a sign that a product has revolutionized, simplified or advanced its category in a distinctive way,” said Dr. Lou Shuman, ‘Best of Class’ founder. “The manufacturers represented here are driving the conversation for how dental practices will operate today and in the future. The foundation for our success in bringing attention to these products has always been our formula: technology leadership in dentistry, unbiased, and not for profit.”
“Best of Class” honorees are chosen by a panel comprised of leading voices in dental technology, who come together each year to discuss, debate and decide what products merit recognition.
All technology categories are considered, but if there is no clear differentiator that sets a product apart in its category, then no winner is selected. Panelists who receive compensation from dental companies are prevented from voting in that company’s category. Over the years, the panel

has developed a rapport that makes space for important conversations about value of different innovations and how evolving categories become more or less valuable to the general dentist. The spirited debate that follows results in a variety of products — obscure and well-known, basic and aspirational — being honored.
“Technology decisions can be expensive and confusing for many doctors. Our job as ‘Best of Class’ panelists is to eat, sleep, live, breath and use technology in our general practices in real, everyday dentistry. We also have a chance to show and discuss these products with dental students and colleagues,” said Dr. John Flucke, writer, speaker and Technology Editor for Dental Products Report. “This allows us to provide recommendations that a doctor and staff can rely on to make informed decisions regarding their technology purchases.”
The panel consists of five dentists with significant knowledge of and experience in dental technology, including Dr. Shuman; Dr. Flucke; Paul Feuerstein, DMD, writer, speaker and Technology Editor for Dentistry Today ; Marty Jablow, DMD, technology writer and consultant for Dr. BiCuspid; and Parag Kachalia, DDS, Vice-Chair of Preclinical Education, Research and Technology, University of Pacific School of Dentistry.
- more -
“There are awards... and there awards. Being recognized as “Best on Class” for the 3rd consecutive year, based upon the criteria “revolutionized, simplified or advanced its category
in a distinctive way” means something very special to us. It means the years of research and development was worth it, that those efforts can and will help change everyday work for a whole work force. We at Doxa feel tremendously honored by this, and as the CEO I am proud a small Swedish company can stand out and make a dent in the global dental field.”
– says Torbjorn Larsson, Doxa CEO
The Pride Institute “Best of Class” Technology awards were launched in 2009 as a new concept to provide an unbiased, non-profit assessment of available technologies in the dental space. Through print and digital media coverage, the “Best of Class” message reaches the community of 150,000 dentists through multiple touch points—in print and online—educating them about the products. Honoree participation in the “Tech Expo” at the American Dental Association’s Annual Meeting offers face-to-face interaction with the companies as well as technology-centered education provided by members of the panel as well as the esteemed consultants of Pride Institute. Courses at last year’s 2014 meeting sold out. This year’s event will be held November 5-10 in Washington, DC.
About Doxa: Doxa is an Uppsala-based company founded in 1987 by Professor Leif Hermansson and his wife Irmeli. Doxa has focused its research and development efforts on the use of bioceramics for orthopedics and odontology. With an extensive patent portfolio, Doxa today is a world leader in the development of proprietary bioceramic technologies which have been reviewed in more than 60 publications. In 2009 Doxa refocused their efforts to develop and market dental materials utilizing these proprietary technologies. Doxa Dental Inc. is the United States subsidiary of Doxa AB Sweden. Find learn more visit: www.CeramirUS.com

Friday, August 14, 2015

NEW EaZy- Primer, from Parkell, Inc


Introducing NEW EaZy- Primer, from Parkell, Inc. - for use when cementing restorative ceramic materials including Zirconia!
This priming agent is specifically formulated with an
MDP monomer added to 4-META, allowing an enhanced bond to the silica-free, polycrystalline structure of Zirconia. Further, EaZy-Primer works terrific with Lithium disilicate and porcelain in conjunction with adhesive resin cements.
With EaZy- Primer, you eliminate the need for the use of hydrofluoric acid, and any of the risks that come with the acid such as discomfort if it comes in contact with soft tissue. EaZy- Primer is simple to use too. After following the instructions for roughening the ceramic surface, all you need is one stroke. To maximize the effectiveness of EaZy Primer, leave it on the surface until it evaporates on its own.  When it dries you’ll notice it glistens, so unlike some other ceramic primers, you can see where you applied it.
EaZy-Primer is the perfect adjunct to any resin cement resulting in strong bonds, beautiful esthetics and ceramic restorations that last!
For more information or to order, contact Parkell, Inc. 800-243-7446 or visit www.parkell.com

Thursday, August 13, 2015

2015 Winners of Prestigious International Periodontal Research Competition VOLPE Prize Honored During Reception at The Ohio State University

-->

Sponsored by Colgate-Palmolive and The Ohio State University, Division of Periodontology, Award Recognizes Year’s Best in Periodontal Clinical Research
by Students in Dentistry

New York, New York (August 11, 2015) – Recognizing the year’s best clinical research in periodontology by students in dentistry, Colgate-Palmolive and The Ohio State University’s College of Dentistry, Division of Periodontology recently announced the 2015 International Periodontal Research Competition VOLPE Prize winners and celebrated their important contributions to the profession.

The University of British Columbia’s Rana Tarzemany won first place for her research on human gingival wound healing and fibroblasts, while Nova Southeastern University’s Nina Cunningham earned second place for her study on the clinical implications of palatal graft procedures. The University of Toronto’s Guy Aboodi took third place for his research on tissue loss and damage in periodontitis.

The winners–along with three honorable mentions–were honored at The Ohio State University (OSU) on July 10 during a special reception attended by a number of pre-doctoral and post-doctoral residents and faculty members of the College of Dentistry’s Division of Periodontology.  Also in attendance was renowned periodontist and award-winning clinical researcher,
Dr. Anthony Volpe, who presented his namesake award to this year’s winners.

Established by OSU and Colgate in 2007, the VOLPE Prize honors Dr. Anthony Volpe’s career spanning over five decades, demonstrating unparalleled commitment to scientific excellence, and yielding countless contributions to the industry, private practice, and academia. Internationally celebrated for leading breakthroughs in periodontology, Dr. Volpe has conducted clinical research all around the world, delivered more than 250 scientific publications and presentations, and earned several patents in dental science from the United States Government. Dr. Volpe has expressed “sincere appreciation” to OSU and Colgate for establishing this award in his honor.

The 2015 VOLPE Prize winners and honorable mentions were among 12 finalists invited to present and defend their research at the International Periodontal Research Competition. These finalists were selected by a panel of judges that included Dr. Thomas Hart, Director of the VOLPE Research Center in Gaithersburg, Maryland. “The International Periodontal Research Competition is truly unique,” said Dr. Hart. “It brings together a diverse group of international researchers in the early stages of their careers, who are united by a common passion to develop better diagnostic and treatment strategies for periodontal diseases.”

The judges’ panel also included OSU College of Dentistry, Associate Professor Dr. Purnima Kumar, and University of Toronto Faculty of Dentistry, Professor Dr. Howard Tenenbaum who noted that “this year’s slate of candidates was probably the most accomplished and wide-ranging we’ve ever seen.” 

For many industry insiders, this award is particularly prestigious because of both the rich history it has honored from the start and the bright futures it celebrates each year. “I believe the VOLPE Prize can be summarized in three thoughts,” said Dr. Angelo Mariotti, OSU College of Dentistry Chair and Professor, Division of Periodontology. “Quality research, the future of periodontics, and the eminence of Tony Volpe”. 

To learn more about the International Periodontal Research Competition VOLPE Prize, visit https://dentistry.osu.edu/academic-divisions/periodontology/volpe-prize.
.


ABOUT COLGATE-PALMOLIVE COMPANY

Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Home Care and Pet Nutrition. Colgate-Palmolive sells its products in over 200 countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Mennen, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Elmex, Tom's of Maine, Sanex, Ajax, Axion, Soupline, and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. For more information about Colgate-Palmolive's global business, visit the Company's web site at www.ColgatePalmolive.com. To learn more about Colgate Bright Smiles, Bright Futures®, Colgate's global oral health education program, please visit www.colgatebsbf.com.
# # #

Wednesday, August 12, 2015

Planmeca Introduces the Planmeca FIT™ System


An Open CAD/CAM System
Chicago, IL, August 11, 2015 - Planmeca announced new branding today for their complete chairside CAD/CAM system. Introducing Planmeca FIT, comprised of the PlanScan scanner, PlanCAD software and PlanMill 40 mill as a fully integrated open CAD/CAM system for same-day dentistry. The FIT system provides a digital workflow that combines exceptional patient experience and convenience as well as high-quality restorations with the perfect fit.
Power of the Perfect FIT
Focusing on a full system approach, the Planmeca FIT will adapt to a practice's schedule, needs and expectations - the perfect fit for today's busy lifestyle. It is the ultimate chairside digital solution to help create a profitable dental practice. Planmeca FIT contains three key components: PlanScan scanner to accurately scan intraorally, PlanCAD software for intuitively designing the restorations, and PlanMill 40 to precisely mill out the restoration in-office. With this complete system, dental professionals can achieve chairside restorations that patients appreciate, all in the same day.

"We wanted to package PlanScan, PlanCAD and PlanMill 40 as a full system that provides the perfect fit in restoration strength and aesthetics, as well as for the patient's health and well-being. The Planmeca FIT open CAD/CAM system allows us to do just that. We have received many positive responses and are very excited to see its powerful impact in the marketplace as we continue to create solutions to better the patient and user experience with our products," said Jukka Kanerva, president of Planmeca CAD/CAM solutions.

Dental patients expect convenience and a comfortable experience. The Planmeca
FIT System exceeds both of these expectations by providing beautiful, natural-looking restorations with the added convenience of same-day dentistry. Restorations fabricated by Planmeca FIT are strong, beautiful, and natural in appearance -
a perfect fit for the ideal smile. With Planmeca FIT same-day technology,
practitioners can now go beyond traditional dentistry and create a new level of exceptional patient experience.

The Planmeca FIT System is distributed exclusively in North America by Henry Schein Dental. For more information about the Planmeca FIT System, visit www.henryscheindental.com or call 1-800-645-6594, prompt #1.
Planmeca OY and Planmeca Group
Planmeca Oy is one of the world's leading dental equipment manufacturers with products ranging from digital dental units, CAD/CAM solutions, world-class 2D and 3D imaging devices to  comprehensive software solutions. Headquartered in Helsinki, Finland, Planmeca's products are distributed in over 120 countries worldwide. With a strong commitment to pioneering innovations & design, it's the largest privately held company in its field. 

Tuesday, August 11, 2015

Gordon’s No. 24 3M Race Car, NASCAR Celebrities Help Drive Smiles and Dental Health through Education Programs at LeGore Boys & Girls Club and Keenan-Stahl Boys & Girls Club



ST. PAUL, Minn., (July 28, 2015) – More than 500 students at LeGore Boys & Girls Club and Keenan-Stahl Boys & Girls Club in Indianapolis participated in a special high-speed oral health education event Thursday that left them with big smiles and new tips for improving their dental health.  It was all thanks to NASCAR Cup Series champion Jeff Gordon, driver of the No. 24 3M Chevrolet SS, NASCAR celebrities, 3M ESPE Dental, the ADA Foundation’s Give Kids A Smile® program, CareCredit, Henry Schein Cares and Church & Dwight.

The ADA Foundation’s Give Kids A Smile program rolled into the Boys & Girls Clubs of Indianapolis as part of the race week at Indianapolis Motor Speedway.  For the past four years, 3M ESPE Dental and 3M Racing have joined forces with the ADA Foundation to bring the Give Kids A Smile program to underserved youth and race fans in conjunction with NASCAR race weekends. 

The students had a chance to hear from Jeff Gordon via video, learn more about NASCAR and 3M Racing from PRN and NASCAR on Sirius host Brad Gillie, and gain invaluable tips for improving their dental health from Dr. Jeff Dalin. They then got to play games and have their photo taken with the No. 24 3M Chevy SS race car.  Every child received a dental gift bag including a Tooth Tunes Spinbrush, toothpaste, a pack of Wrigley Orbit sugar free gum, a dental tips sticker for their bathroom mirror, and a tips card for their parents.

“This is a great event that gets the kids excited about taking care of their dental health,” said Dr. Jeff Dalin.  “The racing theme makes it fun, and Jeff Gordon is very inspirational to them.  When they see him smiling in victory lane, it makes them want have the same kind of smile.”

Gordon, who joined forces with 3M for the 2015 season, is well known for his work with children around the world through Jeff Gordon Children’s Foundation.  Now he brings his passion for children’s oral health to help educate children in need through community and school-based oral health educational programs.  
“This season, our No. 24 3M Chevy SS team is excited to partner with 3M ESPE Dental and the ADA Foundation’s Give Kids A Smile program to help drive smiles and good dental health for children in need,” said Gordon.  “When you look at the life-long impact that poor dental health can have on a young child, you see how important it is to help kids learn good dental health practices.  It makes an incredible difference in their ability to learn, to eat nutritiously and have good self-esteem.”
 
Gordon will help continue the momentum throughout the year. 3M ESPE Dental, the ADA Foundation, CareCredit, Henry Schein Cares, and Church & Dwight, will partner with NASCAR and the No. 24 3M team to deliver the message to some 10,000 underserved elementary school children in four additional race markets.  Programs include fun-filled, high-speed oral health education events featuring the No. 24 3M Chevy SS team and race car.  The goals of the ADA Foundation’s Give Kids A Smile program are to eliminate dental cavities in kids under five and help children learn smart dental health practices that will drive healthy smiles for the rest of their lives.  
As a father of two young children, Gordon understands the challenges that parents and caregivers have in getting kids to routinely practice good dental health habits.

“With good brushing and daily flossing, a smart diet and regular visits to the dentist, all kids can achieve good dental health,” said Gordon.  “It’s all about brushing twice a day for two minutes.  If we can sends kids home from an education event with that message, along with some tips to share with their family members, a great toothbrush, toothpaste and dental floss, we can get them on the right track for a terrific smile.”

"The opportunity to work with Jeff Gordon to educate hundreds of thousands of race fans about good dental health is very powerful," said Jodi Case with 3M ESPE Dental.  “And, we are excited to extend this education program throughout the entire dental community to reach millions more parents and caregivers.  We are so proud to partner with other industry leaders to address this critical issue and drive smiles for children in need."

The ADA Foundation’s Give Kids A Smile program, now in its 13th year, is an access-to-care program that includes more than 1,500 Give Kids A Smile events held throughout the year around the country, through which volunteer dentists and their teams provide free dental services to approximately 350,000 underserved children.

Important Oral Health Messages for Children and Caregivers     
  • Children should brush for two minutes, twice a day.  They should floss once a day as soon as their teeth touch and make smart food choices.
  • Baby teeth are important and they are at risk for decay as soon as they first appear.  Children should see a dentist regularly starting around the time the first tooth erupts or no later than their first birthday.
  • The dentist can show you how to clean tiny teeth properly and how to evaluate habits like thumb sucking.
  • If you have a baby with sore or tender gums, gently rub the gums with a clean finger, cool spoon, or wet gauze to soothe the area.
  •  Children older than two should brush their teeth with a pea-sized amount of fluoride toothpaste.  Be sure they spit it out!
  • Cavity-causing bacteria can be passed from parent to child.  Don’t share a spoon or “clean” a pacifier with your mouth. 

###

About the ADA Foundation
As dentistry's premier philanthropic and charitable organization, the ADA Foundation is a catalyst for uniting people and organizations to make a difference through better oral health. In 2014, the ADA Foundation provided more than $1,335,000 in grants, scholarships, and awards to programs that are in alignment with the organization’s four mission pillars; Charitable Assistance, Access to Care, Research, and Education (C.A.R.E.).  As part of these efforts, the ADA Foundation provides funding to Give Kids A Smile® related efforts and also oversees the Dr. Anthony Volpe Research Center in Gaithersburg, MD (formerly the Paffenbarger Research Center).  For more information about the ADA Foundation, visit www.adafoundation.org
 

About 3M ESPE Dental
3M ESPE Dental is a dental product manufacturer that markets more than 2,000 dental products and services. 3M ESPE Dental products are designed to help dental professionals improve their patients' oral health care. The 3M Digital Oral Care Department, part of the 3M ESPE Dental Division, aims to accelerate and strengthen 3M’s efforts to lead the digital transformation that is occurring in oral care. 3M Health Care, one of 3M’s five Business Groups, provides world-class innovative products and services to help health care professionals improve the practice and delivery of patient care in medical, oral care, drug delivery and health information markets. For more information on the complete 3M ESPE line of dental products, visit the 3M ESPE Dental website at http://www.3MESPE.com or call the 3M ESPE Dental Technical Hotline at 1-800-634-2249. Products are available for purchase through authorized 3M ESPE Dental distributors.


3M and ESPE are trademarks of 3M or 3M Deutschland GmbH.  

About 3M 
3M is a science-based company with a culture of creative collaboration that inspires powerful technologies, making life better. With $32 billion in sales, 3M employs 90,000 people worldwide and has operations in more than 70 countries. For more information, visit www.3M.com or follow @3MNewsroom on Twitter.

About Boys & Girls Clubs of Indianapolis
Since 1893, Boys & Girls Clubs of Indianapolis have served the Indianapolis community.  With 11 Club locations, the Clubs provide programs for over 7,400 youth in the areas of career exploration and educational enhancement, citizenship and leadership, the arts, and health and fitness.  For additional information, please call (317) 920-4700 or visit us online at www.BGCINDY.org and on social media at www.facebook.com/BGCINDY and www.twitter.com/BGCINDY.  


This e-mail is intended only for the named person or entity to which it is addressed and contains valuable business information that is proprietary, privileged, confidential and/or otherwise protected from disclosure. If you received this e-mail in error, any review, use, dissemination, distribution or copying of this e-mail is strictly prohibited. Please notify us immediately of the error via e-mail to help@martinwilliams.com and please delete the e-mail from your system, retaining no copies in any media. We appreciate your cooperation.


This e-mail is intended only for the named person or entity to which it is addressed and contains valuable business information that is privileged, confidential and/or otherwise protected from disclosure. If you received this e-mail in error, any review, use, dissemination, distribution or copying of this e-mail is strictly prohibited. Please notify us immediately of the error via e-mail to help@martinwilliams.com and please delete the e-mail from your system, retaining no copies in any media.  We appreciate your cooperation.


Monday, August 10, 2015

INDEPENDENT CLINICAL STUDY FINDS THE CANARY SYSTEM TO BE SUPERIOR TO BITEWING RADIOGRAPHY



Toronto, Canada - New clinical research findings were announced last week in Boston at the International Association of Dental (IADR) Research General Session. Dr. Ben Amaechi from the University of Texas Health Science Center in San Antonio, who led an independent clinical study, found The Canary System® to exhibit superior performance compared to bitewing radiography for the detection of proximal caries.
Thirty subjects from a mixed population of caries risk patients were involved in the study. The authors of the study found the sensitivity/specificity of The Canary System to be 0.92/0.78 versus 0.67/0.54 for bitewing radiography. The authors of the study concluded that The Canary System is more accurate than bitewing radiography for proximal caries diagnosis.
Bitewing radiographs and visual examination have been considered the gold standard for caries detection but this study along with others demonstrate that The Canary System should become the next gold standard for the detection and monitoring of tooth decay”, said Dr. Stephen Abrams, President of Quantum Dental Technologies Inc, the manufacturer of The Canary System.
Other research presented at IADR included a study showing the effectiveness of The Canary System for detecting smooth surface caries compared to radiography, DIAGNOdent, and Spectra; a study showing excellent intra- and inter-examiner reproducibility of The Canary System for scanning smooth and occlusal surfaces with natural decay; and a report demonstrating the power of combining cloud computing and The Canary System to provide epidemiological data and trends on caries prevalence among populations, age groups, geographies, and tooth type and surface.
The Canary System, with its unique crystal structure diagnostics, allows oral health professionals to detect, image, track and monitor tooth decay on all tooth surfaces, beneath opaque sealants, around the margins of restorations and detect cracks in teeth. The accompanying Canary Cloud (www.thecanarycloud.com) enables dentists to view and manage this data in an online environment, track Canary usage in the office, and keep up- to-date on Canary products and clinical news. With The Canary System, caries detection is not simply shining a light on a tooth surface but it’s about gathering accurate information on the status of the tooth’s crystal structure and then storing it to allow ongoing analysis and monitoring.
Visit www.thecanarysystem.com or email sales@thecanarysystem.com to request additional information.

Friday, August 07, 2015

NYU’s Bluestone Center receives a $369,250 High Priority, Short-Term Project Award from NIDCR to Study Oral Cancer Pain



Drs. Yamano and Schmidt have developed a novel non-viral gene delivery method, and the proposed studies are designed to test whether this could be used to treat cancer pain effectively and safely.

Up to 90% of cancer patients suffer from pain, with oral cancer ranked consistently as one of the most painful cancers. The quality of life for oral cancer patients is the lowest of any patients suffering from cancer because the intense uncontrolled pain interferes with necessary oral functions including eating, talking and swallowing.

“Oral cancer pain is more severe, and the opioid requirement is higher, than pain from any other cancer,” said Dr. Brian L. Schmidt, DDS, MD, PhD, professor in the Department of Oral and Maxillofacial Surgery, and director of NYU’s Bluestone Center for Clinical Research and the NYU Oral Cancer Center. “And in the end, pharmacological agents used to treat cancer pain often lack anatomical specificity and produce off-target effects that create additional suffering.”

“Gene therapy is emerging as an exciting prospect and alternative to opioids for the treatment of cancer pain,” said Dr. Seiichi Yamano, DDS, PhD, DMD, MMSc, assistant professor of prosthodontics at NYU College of Dentistry. “We seek to eliminate oral cancer pain by reversing epigenetic changes using gene therapy and set the stage for a new class of medicines that selectively disrupt nociceptive signaling with limited off-target effects.”

To further their research, the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institute of Health (NIH) has awarded Drs. Schmidt and Yamano a one-year, $369,250 High Priority, Short-Term Project Award (R56) to study the efficacy of a novel non-viral gene delivery method. The proposed studies are designed to test whether nonviral gene delivery into the oral cancer could be used to treat cancer pain effectively and safely.

“Viral vector-based treatment of cancer pain has been evaluated in preclinical studies but problems with immune response, limited DNA carrying capacity, recombination and high cost have been encountered,” said Dr. Schmidt. “Synthetic, non-viral vectors are potential alternatives to viral vectors that preclude these obstacles.”

To improve non-viral gene transfer efficiency, Dr. Yamano recently created two novel nonviral hybrid vectors: a cell-permeable peptide (CPP) combined with either a cationic lipid (CPP/lipid) or a cationic polymer (CPP/polymer). These nonviral vectors have excellent transfection efficiency with little cytotoxicity across a range of cell lines including different types of cancer cells.

The researchers also found that the transfection efficiency using the nonviral vector in oral cancer cells has a significantly higher expression (~8-fold) than normal cells and has a higher expression (~65%) than an adenoviral vector (~50%). In vivo transfection with either of these nonviral vectors leads to high and long-term transgene expression (~7 months) after intramuscular injection of the vectors.

“We recently demonstrated that OPRM1 (the gene for the µ-opioid receptor) is methylated and down regulated in oral cancer compared to matched normal tissues in the same patients; these patients reported pain at the site of cancer,” said Dr. Schmidt. “We further demonstrated that OPRM1 re-expression with viral transduction significantly reduced cancer pain in a mouse model.”

Based on their preliminary work, the researchers hypothesize that re-expression of the OPRM1 gene within oral cancer using our non-viral vectors will attenuate cancer pain and restore orofacial function without excessive toxicity. Their research has three specific aims:

1. To determine the efficacy of ex vivo OPRM1 gene transfer with non-viral vectors to attenuate cancer-induced pain, with the goal to move their method of non-viral transfection to the clinic, with the goal of clinicians directly inoculating their non-viral vector into an oral cancer;

2. To determine the feasibility and efficacy of in vivo OPRM1 gene transfer (i.e. directly into the tongue cancer) with non-viral vectors for attenuation of cancer-induced pain; and

3. To analyze toxicity and immune response in the cancer mice treated with non-viral OPRM1 gene delivery.

“The proposed research is significant because we will use a local delivery technique directly into the cancer to reduce the potential side effects of systemic drugs,” continues Dr. Yamano. “Our approach is innovative because we will transduce the cancer cells for the treatment of cancer pain and our non-viral vector more efficiently targets oral cancer cells relative to normal cells. Ultimately, these studies might facilitate the development of an effective therapy to treat cancer pain.”

The researchers note that, tragically, approximately half of all oral cancer patients will not be cured with surgery, chemotherapy or radiation therapy. Oral cancer is the sixth most common cancer in the US; more patients are afflicted with oral cancer than with melanoma, cervical cancer, or ovarian cancer. The intensity of oral cancer pain escalates with disease progression, and terminal patients generally experience debilitating pain during their final months of life.

NIH NIDCR R56 grant number: R56DE025393 (Schmidt/Yamano)

About the Bluestone Center for Clinical Research--The Bluestone Center for Clinical Research, in conjunction with the NYU Oral Cancer Center, is an academic research organization located at the NYU College of Dentistry. Bluestone's mission is to take a creative scientific approach to transform world health. Bluestone is dedicated to conducting research in oral cancer, cancer symptomology, pharmaceuticals, medical devices, emerging biotechnology, periodontics, implants, and oral health products.
About New York University College of Dentistry Founded in 1865, New York University College of Dentistry (NYUCD) is the third oldest and the largest dental school in the US, educating more than 8 percent of all dentists. NYUCD has a significant global reach and provides a level of national and international diversity among its students that is unmatched by any other dental school.

# # #

Thursday, August 06, 2015

DEXISTM CariVu and DEXIS Imaging Suite Earn “Best of Class” Technology Awards



The prestigious Pride Institute grants esteemed honors to CariVu and DEXIS Imaging Suite for their benefits to the dental practice.
Hatfield, PA (July 21, 2015) DEXIS, LLC, a brand of the KaVo Kerr Group, is pleased to announce that the Pride Institute has presented DEXIS CariVu and DEXIS Imaging Suite with Best of Class Technology Awards for 2015 as products that demonstrate excellence in dental innovation in their respective categories. The Pride Institute “Best of Class” Technology awards were launched 7 years ago as a new concept to provide an unbiased, non-profit assessment of available technologies in the dental space. In 2015, DEXIS CariVu and DEXIS Imaging Suite once again met the rigorous criteria for being “Best of Class,” standing out as innovative products that can positively impact dentists’ daily work.
CariVu technology detects caries* without ionizing radiation. The compact and portable device uses patented transillumination technology to support the identification of occlusal, interproximal and recurrent carious lesions and cracks. And, with images that read like familiar X-ray images, this unit functions unlike any other caries detection device. Another defining aspect of CariVu is its impressive accuracy rate of 99%.*
DEXIS Imaging Suite software has a dynamic history of bringing leading imaging solutions to general dentists and specialists alike. Recognized for its functionality, the software has many unique features that save the practitioner time as well as seamless integration between imaging and the practice management programs, intra-oral cameras, digital panoramic systems and select 3D products.
“Best of Class” Founder, Dr. Lou Shuman, noted, “The ‘Best of Class’ Technology Award continues unparalleled in its integrity and approach to recognizing excellence in dental innovation. Two DEXIS products, the CariVu caries detection device and DEXIS imaging suite, met our distinguished panel’s criteria for adding value to the dental practice and setting a quality standard. CariVu’s transillumination technology offers diagnostic information on caries in a form that is not available in any other current technology. DEXIS Imaging Suite blends technology, integration and functionality for DEXIS users. We recognize DEXIS for its continuing commitment in creating leading edge technologies in the dental space.”
Director of Marketing for DEXIS, Rick Matty said, “DEXIS is honored to accept the ‘Best of Class’ Technology Award. The DEXIS team appreciates the knowledge, experience, and many hours of research that the esteemed panel has dedicated to this arduous process. We are grateful for the recognition of our quality products that enhance the dental experience for clinicians and patients and improve workflow in the office.”
More information on these winning DEXIS products can be found at www.dexis.com/system.
*Kühnisch J. Benefits of the DIAGNOcam Procedure for the Detection and Diagnosis of Caries [study project].

Munich: Ludwig Maximilian University of Munich; 2013. Indications for Use: www.dexis.com/ifu
DX55370715REV0

About DEXIS
DEXIS is an industry leader in developing high quality digital imaging solutions for the dental community. In 1997, DEXIS introduced digital radiography on laptop computers — making it the first truly portable and affordable digital X-ray system. In 2001, DEXISTM became the first intra-oral digital radiography system to be accepted by the American Dental Association into the highly prestigious ADA Seal Program. Today, DEXIS is the most highly awarded intra-oral digital X-ray system with numerous awards from dental researchers and well-respected dental publications. For more information on the DEXIS Imaging Suite of products including the DEXISTM Platinum Sensor and CariVuTM, visit www.dexis.com.
DEXIS is a member of the KaVo Kerr Group. KaVo Kerr Group is a global portfolio of leading dental brands that share common values of Trust, Experience, Choices, Quality and Smart Innovation.
Brands include KaVoTM, KerrTM, Kerr Total CareTM, PentronTM, Axis|SybronTM Endo, OrascopticTM, Pelton & CraneTM, MarusTM, GendexTM, DEXISTM, InstrumentariumTM, SOREDEXTM, i-CATTM, NOMADTM, Implant DirectTM and OrmcoTM. With over 500 years of combined experience and proven solutions, KaVo Kerr Group uniquely serves 99% of all dental practices. Visit
www.kavokerrgroup.com for more information.
About Pride Institute “Best of Class” Technology Award Program
The Pride Institute “Best of Class” Technology awards were launched in 2009 as a new concept to provide an unbiased, non-profit assessment of available technologies in the dental space. Through print and digital media coverage, the “Best of Class” message reaches the community of 150,000 dentists through multiple touch points—in print and online—educating them about the products. Honoree participation in the “Tech Expo” at the American Dental Association’s Annual Meeting offers face-to-face interaction with the companies as well as technology-centered education provided by members of the panel as well as the esteemed consultants of Pride Institute. This year’s event will be held November 5- 10 in Washington, DC.
The panel consists of five dentists with significant knowledge of and experience in dental technology, including Dr. Shuman; Dr. John Flucke, DDS, writer, speaker and Technology Editor for Dental Products Report; Paul Feuerstein, DMD, writer, speaker and Technology Editor for Dentistry Today; Marty Jablow, DMD, technology writer and consultant for Dr. Bicuspid; and Parag Kachalia, DDS, Vice-Chair of Preclinical Education, Research and Technology, University of Pacific School of Dentistry. More information on the Pride Institute can be found at www.prideinstitute.com.